PhaseBio Pharmaceuticals (NASDAQ:PHAS) +81% after-hours as the Food & Drug Administration authorized the company to proceed
with VANGARD, “a potentially pivotal clinical trial to evaluate PB1046
as a treatment for hospitalized COVID-19 patients who are at high risk
for rapid clinical deterioration and acute respiratory distress
syndrome.”
PB1046 is an injected vasoactive intestinal
peptide receptor agonist that targets VPAC receptors in the
cardiovascular, pulmonary and immune systems; VIP has been observed to
have potent bronchodilatory and immunomodulatory effects in the
respiratory system.
Based on FDA feedback, the company believes
“positive, clearly interpretable and clinically meaningful trial results
may enable PhaseBio to submit a Biologics License Application.”
https://seekingalpha.com/news/3578108-phasebio-gets-fda-ok-for-clinical-trial-of-covidminus-19-treatment
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.